Epizyme, Inc. (EPZM): Price and Financial Metrics


Epizyme, Inc. (EPZM): $5.38

0.01 (+0.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EPZM to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

EPZM POWR Grades


  • EPZM scores best on the Growth dimension, with a Growth rank ahead of 65.39% of US stocks.
  • EPZM's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • EPZM ranks lowest in Sentiment; there it ranks in the 8th percentile.

EPZM Stock Summary

  • With a year-over-year growth in debt of 159.71%, Epizyme Inc's debt growth rate surpasses 94.14% of about US stocks.
  • Revenue growth over the past 12 months for Epizyme Inc comes in at 135.59%, a number that bests 95.01% of the US stocks we're tracking.
  • Epizyme Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -26.95%, greater than the shareholder yield of merely 9.77% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Epizyme Inc, a group of peers worth examining would be ACER, PDEX, VSTM, RDUS, and MDWD.
  • EPZM's SEC filings can be seen here. And to visit Epizyme Inc's official web site, go to www.epizyme.com.

EPZM Valuation Summary

  • In comparison to the median Healthcare stock, EPZM's price/sales ratio is 326.32% higher, now standing at 16.2.
  • EPZM's EV/EBIT ratio has moved up 191.6 over the prior 100 months.
  • EPZM's price/sales ratio has moved up 3.5 over the prior 100 months.

Below are key valuation metrics over time for EPZM.

Stock Date P/S P/B P/E EV/EBIT
EPZM 2021-08-31 16.2 7.8 -2.1 -2.8
EPZM 2021-08-30 15.6 7.5 -2.0 -2.7
EPZM 2021-08-27 15.7 7.6 -2.0 -2.8
EPZM 2021-08-26 15.3 7.3 -1.9 -2.7
EPZM 2021-08-25 15.6 7.5 -2.0 -2.8
EPZM 2021-08-24 15.4 7.4 -1.9 -2.7

EPZM Growth Metrics

  • The year over year cash and equivalents growth rate now stands at -58.88%.
  • Its 4 year net income to common stockholders growth rate is now at -104.3%.
  • The 2 year cash and equivalents growth rate now stands at 37.59%.
Over the past 70 months, EPZM's revenue has gone up $20,228,000.

The table below shows EPZM's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 32.582 -227.886 -256.943
2021-03-31 22.039 -223.643 -251.031
2020-12-31 15.762 -206.336 -231.694
2020-09-30 11.681 -188.705 -221.863
2020-06-30 13.83 -184.411 -201.879
2020-03-31 17.263 -173.874 -191.893

EPZM's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EPZM has a Quality Grade of C, ranking ahead of 25.06% of graded US stocks.
  • EPZM's asset turnover comes in at 0.081 -- ranking 280th of 677 Pharmaceutical Products stocks.
  • MTEX, TVTX, and VTVT are the stocks whose asset turnover ratios are most correlated with EPZM.

The table below shows EPZM's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.081 0.731 -0.584
2021-03-31 0.052 0.668 -0.620
2020-12-31 0.036 0.679 -0.669
2020-09-30 0.028 0.722 -0.731
2020-06-30 0.034 0.882 -0.713
2020-03-31 0.044 0.964 -0.691

EPZM Stock Price Chart Interactive Chart >

Price chart for EPZM

EPZM Price/Volume Stats

Current price $5.38 52-week high $14.30
Prev. close $5.37 52-week low $4.72
Day low $5.26 Volume 694,600
Day high $5.45 Avg. volume 1,086,299
50-day MA $6.11 Dividend yield N/A
200-day MA $8.88 Market Cap 550.11M

Epizyme, Inc. (EPZM) Company Bio


Epizyme, Inc. discovers and develops epigenetic therapies for cancer patients. The company was founded in 2007 and is based in Cambridge, Massachusetts.


EPZM Latest News Stream


Event/Time News Detail
Loading, please wait...

EPZM Latest Social Stream


Loading social stream, please wait...

View Full EPZM Social Stream

Latest EPZM News From Around the Web

Below are the latest news stories about Epizyme Inc that investors may wish to consider to help them evaluate EPZM as an investment opportunity.

Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress

CAMBRIDGE, Mass., September 14, 2021--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that clinical data will be presented at the upcoming 2021 European Society of Medical Oncology (ESMO) Virtual Congress, taking place on September 16-21, 2021.

Yahoo | September 14, 2021

Why Is Epizyme (EPZM) Up 3.8% Since Last Earnings Report?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | September 8, 2021

EZH2 Inhibitor Market Witnesses Enormous Opportunities with Daiichi Sankyo, Epizyme, Eternity Bioscience, GSK, Jiangsu HengRui Medicine, Kainos Medicine, OncoFusion, Pfizer

EZH2 Inhibitor Market is projected to hit at $1 Bn by the time duration of 2021-28. EZH2 inhibits genes responsible for suppressing tumor development, and blocking EZH2 activity may slow tumor growth. EZH2 has been targeted for inhibition because it is

OpenPR | September 2, 2021

Rhabdoid Tumor Treatment Market SWOT Analysis, Key Indicators, Forecast 2028 : Takeda Pharmaceutical Company Limited, Chimerix, Epizyme, Inc., Vyriad, DNAtrix, Lantern Pharma, Inc., and Pfizer Inc

Global rhabdoid tumor treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.10% in the above mentioned forecast

OpenPR | August 31, 2021

Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., August 20, 2021--Epizyme (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering novel epigenetic therapies, today announced that the Company approved the grant of equity awards to two new employees with a grant date of August 16, 2021, as equity inducement awards outside of the company's 2013 Stock Incentive Plan and material to the employees’ acceptance of employment with the Company. The equity awards were approved in accordan

Yahoo | August 20, 2021

Read More 'EPZM' Stories Here

EPZM Price Returns

1-mo 0.37%
3-mo -37.37%
6-mo -40.09%
1-year -57.84%
3-year -46.47%
5-year -42.03%
YTD -50.46%
2020 -55.85%
2019 299.35%
2018 -50.92%
2017 3.72%
2016 -24.47%

Continue Researching EPZM

Want to see what other sources are saying about Epizyme Inc's financials and stock price? Try the links below:

Epizyme Inc (EPZM) Stock Price | Nasdaq
Epizyme Inc (EPZM) Stock Quote, History and News - Yahoo Finance
Epizyme Inc (EPZM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8265 seconds.